OBJECTIVE: The aim of this study was to evaluate the association between the methylenetetrahydrofolate reductase (MTHFR) C677T excision repair cross-complementation group 1 (ERCC1) genetic polymorphisms and the clinical efficacy of gemcitabine-based chemotherapy in advanced non-small cell lung cancer (NSCLC). METHODS: A total of 135 chemonaive patients with unresectable advanced NSCLC were treated with gemcitabine/platinum regimens. The polymorphisms of MTHFR C677T, ERCC1 C8092A, and ERCC1 C118T were genotyped using the TaqMan methods. RESULTS: The overall response rate was 28.9%. Patients with MTHFR CC genotype had a higher rate of objective response than patients with variant genotype (TT or CT) (41.2% versus 19.1%, P=0.01). Median time to progression (TTP) of patients with MTHFR CC genotype was longer than that of patients with variant genotype (7.6 months versus 5.0 months, P=0.003). No significant associations were obtained between ERCC1 C118T and C8092A polymorphisms and both response and survival. CONCLUSIONS: Our data suggest the value of MTHFR C677T polymorphism as a possible predictive marker of response and TTP in advanced NSCLC patients treated with gemcitabine/platinum.
OBJECTIVE: The aim of this study was to evaluate the association between the methylenetetrahydrofolate reductase (MTHFR) C677T excision repair cross-complementation group 1 (ERCC1) genetic polymorphisms and the clinical efficacy of gemcitabine-based chemotherapy in advanced non-small cell lung cancer (NSCLC). METHODS: A total of 135 chemonaive patients with unresectable advanced NSCLC were treated with gemcitabine/platinum regimens. The polymorphisms of MTHFRC677T, ERCC1C8092A, and ERCC1C118T were genotyped using the TaqMan methods. RESULTS: The overall response rate was 28.9%. Patients with MTHFR CC genotype had a higher rate of objective response than patients with variant genotype (TT or CT) (41.2% versus 19.1%, P=0.01). Median time to progression (TTP) of patients with MTHFR CC genotype was longer than that of patients with variant genotype (7.6 months versus 5.0 months, P=0.003). No significant associations were obtained between ERCC1C118T and C8092A polymorphisms and both response and survival. CONCLUSIONS: Our data suggest the value of MTHFRC677T polymorphism as a possible predictive marker of response and TTP in advanced NSCLCpatients treated with gemcitabine/platinum.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: T Le Chevalier; G Scagliotti; R Natale; S Danson; R Rosell; R Stahel; P Thomas; R M Rudd; J Vansteenkiste; N Thatcher; C Manegold; J-L Pujol; N van Zandwijk; C Gridelli; J P van Meerbeeck; L Crino; A Brown; P Fitzgerald; M Aristides; J H Schiller Journal: Lung Cancer Date: 2005-01 Impact factor: 5.705
Authors: D Isla; C Sarries; R Rosell; G Alonso; M Domine; M Taron; G Lopez-Vivanco; C Camps; M Botia; L Nuñez; M Sanchez-Ronco; J J Sanchez; M Lopez-Brea; I Barneto; A Paredes; B Medina; A Artal; P Lianes Journal: Ann Oncol Date: 2004-08 Impact factor: 32.976
Authors: David R Gandara; Tomoya Kawaguchi; John Crowley; James Moon; Kiyoyuki Furuse; Masaaki Kawahara; Satoshi Teramukai; Yuichiro Ohe; Kaoru Kubota; Stephen K Williamson; Oliver Gautschi; Heinz Josef Lenz; Howard L McLeod; Primo N Lara; Charles Arthur Coltman; Masahiro Fukuoka; Nagahiro Saijo; Masanori Fukushima; Philip C Mack Journal: J Clin Oncol Date: 2009-05-26 Impact factor: 44.544
Authors: Aristea Kalikaki; Maria Kanaki; Helen Vassalou; John Souglakos; Alexandra Voutsina; Vassilis Georgoulias; Dimitris Mavroudis Journal: Clin Lung Cancer Date: 2009-03 Impact factor: 4.785